362 related articles for article (PubMed ID: 23449384)
21. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.
Waters V
Curr Pharm Des; 2012; 18(5):696-725. PubMed ID: 22229574
[TBL] [Abstract][Full Text] [Related]
22. Lung transplantation in cystic fibrosis patients with difficult to treat lung infections.
Dupont L
Curr Opin Pulm Med; 2017 Nov; 23(6):574-579. PubMed ID: 28858970
[TBL] [Abstract][Full Text] [Related]
23. Cystic fibrosis: infection.
Høiby N
Schweiz Med Wochenschr; 1991 Jan; 121(4):105-9. PubMed ID: 1900640
[TBL] [Abstract][Full Text] [Related]
24. Upper aero-digestive contamination by Pseudomonas aeruginosa and implications in Cystic Fibrosis.
Rivas Caldas R; Boisramé S
J Cyst Fibros; 2015 Jan; 14(1):6-15. PubMed ID: 24933711
[TBL] [Abstract][Full Text] [Related]
25. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation.
Bonvillain RW; Valentine VG; Lombard G; LaPlace S; Dhillon G; Wang G
J Heart Lung Transplant; 2007 Sep; 26(9):890-7. PubMed ID: 17845927
[TBL] [Abstract][Full Text] [Related]
26. Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen.
Hansen CR
Curr Opin Pulm Med; 2012 Nov; 18(6):628-31. PubMed ID: 22990659
[TBL] [Abstract][Full Text] [Related]
27. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
28. [Antibiotic treatment of cystic fibrosis].
de Montalembert M; Berche P; Lenoir G
Ann Pediatr (Paris); 1991 Oct; 38(8):523-8. PubMed ID: 1746849
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial peptide therapeutics for cystic fibrosis.
Zhang L; Parente J; Harris SM; Woods DE; Hancock RE; Falla TJ
Antimicrob Agents Chemother; 2005 Jul; 49(7):2921-7. PubMed ID: 15980369
[TBL] [Abstract][Full Text] [Related]
30. Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.
Kubesch P; Lingner M; Grothues D; Wehsling M; Tümmler B
Scand J Gastroenterol Suppl; 1988; 143():77-80. PubMed ID: 3133755
[TBL] [Abstract][Full Text] [Related]
31. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.
Krzewinski JW; Nguyen CD; Foster JM; Burns JL
J Clin Microbiol; 2001 Oct; 39(10):3597-602. PubMed ID: 11574579
[TBL] [Abstract][Full Text] [Related]
32. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
Murray TS; Egan M; Kazmierczak BI
Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
[TBL] [Abstract][Full Text] [Related]
33. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence.
Bragonzi A; Paroni M; Nonis A; Cramer N; Montanari S; Rejman J; Di Serio C; Döring G; Tümmler B
Am J Respir Crit Care Med; 2009 Jul; 180(2):138-45. PubMed ID: 19423715
[TBL] [Abstract][Full Text] [Related]
34. [Bacterial infections and resistance to antibiotics in cystic fibrosis].
Taccetti G; Repetto T; Procopio E; Marianelli L; Campana S
Pediatr Med Chir; 1999; 21(5 Suppl):213-8. PubMed ID: 10963010
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
36. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
37. [Isolated pathogen microorganisms in respiratory samples from children with cystic fibrosis].
Anzaudo MM; Busquets NP; Ronchi S; Mayoral C
Rev Argent Microbiol; 2005; 37(3):129-34. PubMed ID: 16323660
[TBL] [Abstract][Full Text] [Related]
38. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
Murray TS; Stanley G; Koff JL
Infect Dis Clin North Am; 2024 Mar; 38(1):149-162. PubMed ID: 38280761
[TBL] [Abstract][Full Text] [Related]
39. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway.
Fick RB; Sonoda F; Hornick DB
Semin Respir Infect; 1992 Sep; 7(3):168-78. PubMed ID: 1475541
[TBL] [Abstract][Full Text] [Related]
40. Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients.
Velikova N; Wells JM
Curr Drug Targets; 2017; 18(6):687-695. PubMed ID: 26853320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
